Original Research

Online Only

Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma

Original Research, Adverse Events, Disparities in Oncology, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma

April 2026 Vol 19, No 2

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and Europe.

Laura Fan Sun, PharmD, BCOP; Natalie Brumwell, PharmD; Kevin Hall, PharmD; Kristina Murphy, PharmD; Jeffrey Switchenko, PhD; Yichun Cao, MPH; Vikas Gupta, MD, PhD; Madhav Dhodapkar, MBBS; Nisha Joseph, MD; Craig Hofmeister, MD, MPH; Jonathan Kaufman, MD; Ajay Nooka, MD, MPH, FACP; Sagar Lonial, MD; Kathryn Maples, PharmD